Mepolizumab improves small airway function in severe eosinophilic asthma
نویسندگان
چکیده
منابع مشابه
Mepolizumab (Nucala) For Severe Eosinophilic Asthma.
Mepolizumab (Nucala) for severe eosinophilic asthma.
متن کاملMepolizumab in refractory eosinophilic asthma.
In a recent Lung Alert reviewing our study of mepolizumab in severe eosinophilic asthma, Barratt states that the study population represented a minority of patients with asthma and that they had corticosteroidresistant disease. These comments require clarification. While we accept that the population studied by us represents about 3% of the total asthma population, it was 30% of patients with r...
متن کاملClinical usefulness of mepolizumab in severe eosinophilic asthma
Asthma is a chronic inflammatory disorder of the airways with variable clinical severity from very mild and occasional symptoms to recurrent critical exacerbations, at risk of fatal or near-fatal outcome, in a small percentage of patients. Within the different inflammatory cascades involved in asthma, eosinophils play a central role in the pathogenesis and largely influence disease severity. In...
متن کاملMepolizumab treatment in patients with severe eosinophilic asthma.
BACKGROUND Some patients with severe asthma have frequent exacerbations associated with persistent eosinophilic inflammation despite continuous treatment with high-dose inhaled glucocorticoids with or without oral glucocorticoids. METHODS In this randomized, double-blind, double-dummy study, we assigned 576 patients with recurrent asthma exacerbations and evidence of eosinophilic inflammation...
متن کاملAirway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
BACKGROUND Anti-interleukin (IL)-5 monoclonal antibodies as an eosinophil-depleting strategy is well established, with Mepolizumab being the first biologic approved as an adjunct treatment for severe eosinophilic asthma. CASE PRESENTATION A 62-year old woman diagnosed with severe eosinophilic asthma showed poor response to Mepolizumab therapy (100 mg subcutaneous dose/monthly) and subsequent ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Respiratory Medicine
سال: 2019
ISSN: 0954-6111
DOI: 10.1016/j.rmed.2019.01.016